Structure Therapeutics Inc.
GPCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Structure Therapeutics Inc. (GPCR) is listed under Biotechnology. The $2.74B market capitalization puts GPCR squarely in mid-cap range for its industry. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Market Cap
$2.74B
Beta
-1.39
P/E (TTM)
—
P/E (Fwd)
-19.76
EPS (TTM)
$-2.64
EPS (Fwd)
$-1.95
ROE
-11.9%
ROA
-9.4%
Cash
$1.45B
Total Debt
$6.5M
Free CF
-$180.0M
52W Change
75.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.45B in cash comfortably exceeding the $6.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$180.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -11.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
GPCR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Structure Therapeutics Inc. and its sector.